← All Pasithea Therapeutics CORP filings

Pasithea Therapeutics CORP Form 4 insider transactions

NASDAQ
KTTA
Pasithea Therapeutics CORP
Form 4: Pasithea Therapeutics CEO Tiago Marques Acquires Stock Options
CEO Tiago Marques of Pasithea Therapeutics Corp. reports acquisition of stock options on March 1, 2024.
NASDAQ
KTTA
Pasithea Therapeutics CORP
Form 4: Pasithea Therapeutics Director Emer Leahy Acquires Stock Options
Director Emer Leahy acquired stock options in Pasithea Therapeutics Corp. on March 1, 2024, according to a Form 4 filing with the SEC.
NASDAQ
KTTA
Pasithea Therapeutics CORP
Form 4: Pasithea Therapeutics Director Acquires Stock Options
Director Simon Dumesnil acquired stock options in Pasithea Therapeutics Corp. on March 1, 2024, according to a Form 4 filing.
NASDAQ
KTTA
Pasithea Therapeutics CORP
Form 4: Pasithea Therapeutics Executive Awarded Stock Options
Graeme Currie, Chief Development Officer of Pasithea Therapeutics, was granted fully vested stock options exercisable immediately.